Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2025
|
| Online Access: | https://doi.org/10.5281/zenodo.15000574 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- <div> <p><em><span>Gastrointestinal tract (GIT) disorders, including irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and inflammatory bowel disease (IBD), significantly<span> </span>affect millions of people worldwide, leading to chronic pain, digestive dysfunction, and reduced quality of life. Current pharmacological treatments primarily focus on symptom management rather than addressing underlying<span> </span>causes.<span> </span>Recent<span> </span>advances<span> </span>in<span> </span>molecular<span> </span>medicine,<span> </span>gene<span> </span>therapy,<span> </span>microbiome<span> </span>research,<span> </span>and nanomedicine have introduced innovative therapeutic strategies for GIT disorders. This review explores<span> </span>cutting-edge<span> </span>pharmacological<span> </span>interventions,<span> </span>including<span> </span>biologics,<span> </span>small-molecule<span> </span>inhibitors, RNA-based therapies, probiotics, and nanotechnology-driven drug delivery systems. Additionally, challenges related to drug bioavailability, patient adherence, and regulatory approvals are discussed. By presenting a comprehensive overview of these novel approaches, this review aims to highlight the future of GIT disorder management.</span></em></p> <h1><em><span>Keywords: </span></em><em><span>Gastrointestinal<span> </span>disorders,<span> </span>Nanomedicine,<span> </span>Gut<span> </span>microbiome,<span> </span>Biologics,<span> </span>Gene<span> therapy</span></span></em></h1> </div>